LTRNHealthcare · BiotechnologyThe 2 Wall Street analysts covering Lantern Pharma, Inc. hold a median 12-month price target of $18 — +923.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 54 of 100 as at 12 Sept 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores Lantern Pharma, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (88): Smaller than most of the companies we track.
Quality (15): Profits are thin or unreliable for the size of the business, or they are not turning into cash.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on LTRN, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +923.4% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 2 Apr 2025 | Lake Street | Initiates | Buy | — |
| 2 Apr 2025 | Lake Street | Initiates | Buy | $25 |
| 25 Apr 2024 | HC Wainwright & Co. | Reiterates | Neutral | — |
| 10 Aug 2023 | EF Hutton | Reiterates | Buy | — |
| 26 June 2023 | EF Hutton | Maintains | Buy | — |
| 25 May 2023 | EF Hutton | Assumes | Buy | $11 |
| 18 May 2023 | HC Wainwright & Co. | Initiates | Neutral | — |
| 21 Mar 2023 | EF Hutton | Reiterates | Buy | — |
| 15 Feb 2023 | EF Hutton | Maintains | Buy | — |
| 1 Nov 2022 | EF Hutton | Initiates | Buy | — |
| 11 Mar 2022 | HC Wainwright & Co. | Maintains | Buy | — |
| 2 Nov 2021 | HC Wainwright & Co. | Maintains | Buy | — |
| 7 Oct 2021 | HC Wainwright & Co. | Initiates | Buy | — |
| 28 July 2020 | Colliers Securities | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. LTRN appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 11 Sept 2026, Lantern Pharma, Inc. returned −56.5% against +17.5% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 82% of US stocks
Cheaper than 97% of US stocks
Cheaper than 67% of US stocks
Higher than 32% of US stocks
Higher than 30% of US stocks
Higher than 4% of US stocks
Higher than 5% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Lantern Pharma, Inc. has a market value of $21.9M and an enterprise value of $14.5M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$18.7M.
Free cash flow in the twelve months to 30 June 2026: −$14.1M.
Trailing P/E: −1.1×; forward P/E: −0.8× — the forward figure prices analyst consensus estimates, not reported earnings.
Lantern Pharma, Inc. employs 16 people.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Lantern Pharma, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Lantern Pharma Inc. (LTRN) held its Q2 2026 earnings call, and a transcript of the call was published by Seeking Alpha. The excerpt provides the headline and source information for the earnings call transcript.
Why it matters — LTRN watchers would care because the earnings call transcript is a key source of detail on the company's quarterly results and management commentary.
Lantern Pharma reported its second quarter 2026 financial results and provided a business update, as announced by the company. The release presents the company's quarterly financial figures alongside an update on its operations.
Why it matters — LTRN watchers would care because the quarterly financial results and business update offer the latest official information on the company's financial performance and strategic progress.
Lantern Pharma announced it will report its second quarter 2026 operating and financial results on August 14th, 2026 at 9:00 a.m. ET, according to a Business Wire release.
Why it matters — LTRN watchers can mark the calendar for the upcoming earnings report, which will provide updates on the company's quarterly operating and financial performance.
Lantern Pharma (Nasdaq: LTRN) launched Open-Medicine AI as a separate company to commercialize and expand its multi-agent AI co-scientist platform for the transformation of medicine. The new entity was established through a separation from Lantern Pharma, according to the announcement.
Why it matters — LTRN watchers would care because the company is expanding and commercializing its AI platform through a newly formed separate entity, which broadens the reach of its technology.
Lantern Pharma is advancing its EMA-cleared Phase 1b/2 clinical trial of LP-184 (Zirdafulven) for biomarker-selected advanced bladder cancer.
Why it matters — This trial advancement signals that Lantern Pharma is progressing LP-184, a key pipeline candidate, into a later-stage study for a specific cancer population in a major regulatory region.
The 2 Wall Street analysts covering Lantern Pharma, Inc. have a median 12-month price target of $18, with estimates ranging from $10 to $25. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 2 analysts covering Lantern Pharma, Inc., 2 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Lantern Pharma, Inc. 54 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.
As at 12 Sept 2026, Lantern Pharma, Inc. ranks 54 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (88 of 100).
No one can know that. What the data says: the median 12-month target from 2 analysts implies +923.4% from the last close, and Ticker Nerd's factor model ranks Lantern Pharma, Inc. 54 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Lantern Pharma, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for LTRN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $10 to $25 over the next 12 months.
Lantern Pharma, Inc. returned -56.5% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.
Lantern Pharma Inc. is a clinical-stage biotechnology company focused on oncology drug discovery and development.
The most recent item we track (Seeking Alpha, 14 Aug 2026): "Lantern Pharma Inc. (LTRN) Q2 2026 Earnings Call Transcript". Lantern Pharma Inc. (LTRN) held its Q2 2026 earnings call, and a transcript of the call was published by Seeking Alpha. The excerpt provides the headline and source information for the earnings call transcript.
Lantern Pharma Inc. is a clinical-stage biotechnology company focused on oncology drug discovery and development. Lantern Pharma uses artificial intelligence, machine learning, and genomic data through its proprietary RADR platform to identify precision cancer therapies and match them with the patient groups most likely to benefit. Its current portfolio includes multiple lead drug candidates and an antibody-drug conjugate program spanning several cancer indications, including solid tumors, blood cancers, and rare oncology settings. The company’s work centers on accelerating the development of targeted cancer treatments and improving the efficiency of clinical research through data-driven drug design and patient selection. Lantern Pharma Inc. is based in Dallas, Texas, and operates at the intersection of biotechnology, computational biology, and precision medicine.
CEO Mr. Panna Sharma · 16 employees · United States · https://www.lanternpharma.com
